When to Consider Scrofula (Tuberculous Cervical Lymphadenitis)
Consider scrofula in any patient presenting with persistent, painless cervical lymphadenopathy, particularly when the mass is unilateral, lacks warmth or erythema (a "cold abscess"), and persists beyond 2-3 weeks despite standard antibiotic therapy.
High-Risk Clinical Scenarios Requiring Immediate Consideration
You should have a high index of suspicion for scrofula in the following situations:
Epidemiological risk factors: Patients from or with recent travel to TB-endemic countries (South Asia, Sub-Saharan Africa, Latin America), history of latent TB infection, known TB exposure, or immigrant/refugee status 1, 2, 3
Classic presentation: Painless, slowly enlarging cervical mass (typically 4-8 weeks duration) without local inflammatory signs—this "cold abscess" is pathognomonic 1, 4, 2
Failed empirical therapy: Cervical lymphadenopathy that does not respond to standard bacterial antibiotics after 2-3 weeks 1, 4
Special populations: Elderly patients with prior oncological history where malignancy is initially suspected but imaging/cytology is atypical 4
Concurrent findings: Patients with known pulmonary TB or positive latent TB testing 1, 5
Key Diagnostic Pitfalls to Avoid
The evidence reveals critical diagnostic challenges that lead to delays:
Fragmented medical records across healthcare systems can obscure a history of latent TB infection, leading to misdiagnosis 1. Always directly ask about prior TB testing and treatment, regardless of what appears in the current medical record.
Mimicry of malignancy is common, especially in elderly patients or those with cancer history 4. The rapid enlargement and firm consistency can suggest lymphoma or metastatic disease, but the absence of systemic B-symptoms and the "cold" nature of the mass should redirect suspicion toward TB.
Multiple inconclusive tests are typical in scrofula 1. Initial fine-needle aspiration cytology (FNAC) may be non-diagnostic, requiring repeat procedures or excisional biopsy. Do not abandon the diagnosis after one negative test if clinical suspicion remains high.
Diagnostic Approach
When scrofula is suspected:
Obtain FNAC immediately as the first-line diagnostic tool—it can demonstrate caseous-purulent material and exclude carcinoma 4. If initial FNAC is inconclusive, proceed directly to excisional biopsy rather than repeating FNAC multiple times.
Send specimens for both cytology AND culture: Microbiological confirmation is essential even when pathology suggests TB 5. Culture for Mycobacterium tuberculosis provides definitive diagnosis and drug susceptibility testing.
Test for latent TB infection using IGRA (preferred over TST in BCG-vaccinated individuals) 6, though this does not distinguish active from latent disease.
Image the chest to evaluate for concurrent pulmonary TB, present in a minority of cases 5.
Consider ultrasound which may reveal cystic masses with internal septations and multiple hypoechoic lesions 2.
Geographic Considerations
Even in low-prevalence regions like Wisconsin or Italy, scrofula is re-emerging 1, 4. Do not dismiss TB based solely on geographic location—the increasing immigrant population and global travel mean TB must remain in your differential for chronic cervical lymphadenopathy regardless of practice location 3.
Treatment Implications
Once diagnosed, scrofula responds excellently to standard 6-month anti-tuberculous therapy (2 months of isoniazid, rifampin, pyrazinamide, and ethambutol, followed by 4 months of isoniazid and rifampin) 7, 5. Lymph nodes may paradoxically enlarge during treatment without representing treatment failure 7. Surgical excision is reserved for diagnostic purposes or unusual circumstances, not routine treatment 7.
The key to avoiding morbidity and mortality is early consideration and diagnosis—delays from misdiagnosis as bacterial infection or malignancy lead to prolonged illness and potential complications 1, 4.